title: Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
authors.affiliation: Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, Devon, UK.
authors.forename: David L
authors.initials: DL
authors.lastname: Tucker
authors.affiliation: Department of Haematology, Royal Cornwall Hospital, Truro, UK.
authors.forename: Georgina
authors.initials: G
authors.lastname: Naylor
authors.affiliation: Department of Haematology, Royal Cornwall Hospital, Truro, UK.
authors.forename: Anton
authors.initials: A
authors.lastname: Kruger
authors.affiliation: Department of Haematology, Royal Devon and Exeter Hospital, Exeter, UK.
authors.forename: Malcolm S
authors.initials: MS
authors.lastname: Hamilton
authors.affiliation: Addenbrooke's Hospital, Cambridge, UK.
authors.forename: George
authors.initials: G
authors.lastname: Follows
authors.affiliation: Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, Devon, UK.
authors.forename: Simon A
authors.initials: SA
authors.lastname: Rule
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: central nervous system; ibrutinib; lymphoma